Price revision and bans

| Updated on: Mar 18, 2016

A couple of key developments impacting the pharmaceutical industry come up in the next two weeks. The annual price revision that companies are allowed to make in line with the Wholesale Price Index will happen, in April. This time a downward revision (about – 2.75 per cent) is expected, a departure from the price hikes seen last year. The coming week will also see hearings on several cases filed in the Delhi High Court on the recent controversy over the 343-fixed doze combinations banned by the Health Ministry. A handful of companies have got interim stay orders from the court against the ban on their combination drugs. Monday will see the next hearing on these cases that affect Pfizer, Abbott, Glenmark, Alembic, Macleods, Procter & Gamble and Reckitt Benckiser.

Published on January 20, 2018

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you